LeMaitre Vascular, Inc. $LMAT Shares Sold by Copeland Capital Management LLC

Key Points

• Copeland Capital Management reduced its stake in LeMaitre Vascular by 5.5% in Q4, selling 51,351 shares and ending the quarter with 888,977 shares (about 3.92% of the company, valued at ~$72.1M).
• Insiders sold heavily: executives disposed of 215,438 shares in the last quarter, including CEO George W. Lemaitre's sale of 55,930 shares for ~$6.03M, leaving insiders owning roughly 9.5% of the stock.
• Business results and shareholder returns: LeMaitre beat Q results with $0.68 EPS on $64.45M revenue (up 15.7% y/y), provided FY2026 EPS guidance of 2.810–3.010, and raised its quarterly dividend to $0.25 ($1.00 annually, ~0.9% yield).

Copeland Capital Management LLC lessened its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 888,977 shares of the medical instruments supplier's stock after selling 51,351 shares during the quarter. LeMaitre Vascular comprises approximately 1.6% of Copeland Capital Management LLC's investment portfolio, making the stock its 11th largest holding. Copeland Capital Management LLC owned 3.92% of LeMaitre Vascular worth $72,096,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State of Alaska Department of Revenue boosted its position in LeMaitre Vascular by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier's stock worth $971,000 after purchasing an additional 147 shares in the last quarter. Johnson Investment Counsel Inc. boosted its position in LeMaitre Vascular by 0.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier's stock worth $2,607,000 after purchasing an additional 153 shares in the last quarter. Federated Hermes Inc. boosted its position in LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier's stock worth $3,294,000 after purchasing an additional 155 shares in the last quarter. Jones Financial Companies Lllp boosted its position in LeMaitre Vascular by 2.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier's stock worth $630,000 after purchasing an additional 158 shares in the last quarter. Finally, Illinois Municipal Retirement Fund boosted its position in LeMaitre Vascular by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier's stock worth $967,000 after purchasing an additional 171 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $112.90 on Friday. The company's fifty day moving average price is $106.70 and its 200 day moving average price is $93.04. LeMaitre Vascular, Inc. has a 1 year low of $78.01 and a 1 year high of $118.01. The stock has a market capitalization of $2.58 billion, a P/E ratio of 44.98, a P/E/G ratio of 3.25 and a beta of 0.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm had revenue of $64.45 million for the quarter, compared to analysts' expectations of $62.98 million. During the same quarter last year, the company earned $0.49 EPS. The firm's revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were paid a $0.25 dividend. The ex-dividend date of this dividend was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.20. LeMaitre Vascular's dividend payout ratio is 39.84%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LMAT shares. Wells Fargo & Company upped their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 26th. Roth Mkm restated a "buy" rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Barrington Research upped their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Zacks Research upgraded LeMaitre Vascular from a "hold" rating to a "strong-buy" rating in a research report on Monday, April 13th. Finally, Citizens Jmp upped their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of "Moderate Buy" and a consensus target price of $105.80.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 55,930 shares of LeMaitre Vascular stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total value of $6,029,813.30. Following the sale, the chief executive officer owned 1,476,500 shares of the company's stock, valued at approximately $159,181,465. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.